Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Aptevo Therapeutics Inc. (APVO : NSDQ)
 
 • Company Description   
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.

Number of Employees: 58

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.03 Daily Weekly Monthly
20 Day Moving Average: 10,516,872 shares
Shares Outstanding: 4.90 (millions)
Market Capitalization: $34.43 (millions)
Beta: 6.85
52 Week High: $46.66
52 Week Low: $6.38
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -55.19% -53.80%
12 Week -58.67% -59.08%
Year To Date -80.82% -82.00%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2401 4TH AVENUE SUITE 1050
-
SEATTLE,WA 98121
USA
ph: 206-838-0500
fax: 206-838-0503
ir@apvo.com http://www.aptevotherapeutics.com
 
 • General Corporate Information   
Officers
Marvin L. White - President; Chief Executive Officer
Fuad El-Hibri - Chairman of the Board of Directors
Jeffrey Lamothe - Senior Vice President and Chief Financial Officer
Barbara Lopez Kunz - Director
Daniel J. Abdun-Nabi - Director

Peer Information
Aptevo Therapeutics Inc. (CORR.)
Aptevo Therapeutics Inc. (RSPI)
Aptevo Therapeutics Inc. (CGXP)
Aptevo Therapeutics Inc. (BGEN)
Aptevo Therapeutics Inc. (GTBP)
Aptevo Therapeutics Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03835L207
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 02/11/22
Share - Related Items
Shares Outstanding: 4.90
Most Recent Split Date: 3.00 (0.07:1)
Beta: 6.85
Market Capitalization: $34.43 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.29 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-5.95 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.72
Price/Cash Flow: -
Price / Sales: 3.13
EPS Growth
vs. Year Ago Period: 32.56%
vs. Previous Quarter: 18.54%
Sales Growth
vs. Year Ago Period: 111.62%
vs. Previous Quarter: -0.45%
ROE
09/30/21 - -248.45
06/30/21 - -276.54
03/31/21 - -301.36
ROA
09/30/21 - -46.52
06/30/21 - -51.65
03/31/21 - -64.17
Current Ratio
09/30/21 - 1.82
06/30/21 - 2.13
03/31/21 - 2.14
Quick Ratio
09/30/21 - 1.82
06/30/21 - 2.13
03/31/21 - 2.14
Operating Margin
09/30/21 - -272.56
06/30/21 - -318.70
03/31/21 - -424.84
Net Margin
09/30/21 - -265.80
06/30/21 - -309.94
03/31/21 - -414.61
Pre-Tax Margin
09/30/21 - -272.56
06/30/21 - -318.70
03/31/21 - -424.84
Book Value
09/30/21 - 1.49
06/30/21 - 3.12
03/31/21 - 2.36
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - 0.55
06/30/21 - 0.31
03/31/21 - 0.44
Debt-to-Capital
09/30/21 - 35.49
06/30/21 - 23.75
03/31/21 - 30.52
 

Powered by Zacks Investment Research ©